Vale S.A. (BVMF:VALE3)
52.10
-1.35 (-2.53%)
May 30, 2025, 5:12 PM GMT-3
Vale S.A. Revenue
Vale S.A. had revenue of 47.41B BRL in the quarter ending March 31, 2025, with 13.18% growth. This brings the company's revenue in the last twelve months to 211.53B, up 2.62% year-over-year. In the year 2024, Vale S.A. had annual revenue of 206.01B, down -0.99%.
Revenue (ttm)
211.53B
Revenue Growth
+2.62%
P/S Ratio
1.05
Revenue / Employee
3.27M
Employees
64,616
Market Cap
222.40B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 206.01B | -2.06B | -0.99% |
Dec 31, 2023 | 208.07B | -18.44B | -8.14% |
Dec 31, 2022 | 226.51B | -67.02B | -22.83% |
Dec 31, 2021 | 293.52B | 87.43B | 42.42% |
Dec 31, 2020 | 206.10B | 61.46B | 42.50% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Suzano | 49.50B |
CSN Mineração | 16.90B |
Companhia Siderúrgica Nacional | 44.88B |
São Martinho | 7.85B |
Três Tentos Agroindustrial S/A | 13.65B |
Dexco | 8.20B |
Companhia Brasileira de Alumínio | 8.82B |
Boa Safra Sementes | 1.90B |
Vale S.A. News
- 1 day ago - Vale: Betting On Buybacks And Relevant Upside - Seeking Alpha
- 3 days ago - Exclusive: Miner Vale misses deadline for power to expand Brazil nickel complex - Reuters
- 5 days ago - More Than Iron - Vale's Strategic Pivot To Critical Metals - Seeking Alpha
- 13 days ago - What's Next With VALE Stock? - Forbes
- 17 days ago - Dismantling of Sudbury's Superstack could start this summer, says Vale - CBC News
- 18 days ago - 5 Ideal 'Safer' Dividend Buys From Bloomberg's May Watchlist - Seeking Alpha
- 18 days ago - AviadoBio Announces ASPIRE-FTD Phase 1/2 Clinical Trial in the UK at Cambridge University Hospitals NHS Foundation Trust, Cardiff and Vale University Health Board, and University College London - Business Wire
- 23 days ago - How Is The Market Feeling About Vale? - Benzinga